Pregabalin Capsule
Product Images NDC 70518-4585

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4585). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin Capsule C-V 50 mg oral capsules, repackaged by RemedyRepack Inc. The label shows a quantity of 90 capsules and includes storage instructions (20-25°C with permitted excursions to 15-30°C), a caution about federal law prohibiting transfer, and contact information for the repackager. The label also includes lot and expiry fields, with NDC 70518-4585-00 and manufacturer details for Camber Pharma, Inc.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The chart compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, with lines indicating the improvement trends over increasing percent pain improvement.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A line graph comparing the estimated percentage of subjects without LTR over a period of 180 days between Pregabalin and placebo groups. The Y-axis represents the estimated percentage without LTR, ranging from 0% to 100%, and the X-axis shows time in days from 0 to 180. Two lines are shown: a solid line for Pregabalin and a dashed line for placebo, illustrating differences in outcomes over time.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

Line chart showing the percent of subjects improved over time from baseline to Week 12 based on the percent improvement scale. Two lines represent the effects of Pregabalin and Placebo, with Pregabalin showing a higher percentage of subjects improved throughout the time range compared to Placebo.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line chart comparing the percent of subjects improved over time between Pregabalin and Placebo groups. The x-axis shows percent improved from baseline to Week 16 BOCF, and the y-axis shows percent of subjects improved, with separate solid and dashed lines representing Pregabalin and Placebo, respectively.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph depicting the percent of patients improved plotted against the percent improvement in pain from baseline, comparing Pregabalin 100 mg taken three times a day with placebo. The y-axis shows the percent of patients improved, ranging from 0 to 100, while the x-axis indicates percent improvement in pain from baseline.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Four lines represent Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, and a placebo group, illustrating comparative patient improvement percentages across these dosing regimens.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph showing the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with the Pregabalin 200 mg group showing higher patient improvement rates.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin 50 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph compares treatment efficacy among these groups over varying pain improvement thresholds.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar chart comparing responder rates (%) at varying dosages of Pregabalin and placebo across two studies (Study E1 and Study E3). The chart shows increasing responder rates with higher Pregabalin dosages compared to placebo, with statistical significance indicated. Sample sizes (N) for each group are noted below the bars.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A line graph showing the median percent change in seizure reduction from baseline plotted against doses of Pregabalin (mg/day) up to 600 mg. Four study groups are represented with different symbols, each showing increasing seizure reduction with higher doses. Significant p-values are noted at various points to highlight statistical significance compared to placebo.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A bar chart showing responder rates (%) for Pregabalin at different doses compared to placebo. The x-axis lists placebo (93 subjects), 2.5 mg/kg/day (103 subjects), and 10 mg/kg/day (96 subjects). The y-axis displays responder rates, with placebo at 22.6%, 2.5 mg/kg/day at 29.1%, and 10 mg/kg/day at 40.6%.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 600 mg, 450 mg, 300 mg, and placebo. The graph includes four lines representing each dose group, indicating decreasing patient improvement percentages as pain improvement increases from 0 to 100 percent.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of Pregabalin, showing its molecular arrangement with an amino group, a carboxylic acid group, and a branched carbon chain with a methyl substituent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.